DEPO-PROVERA vs FOTIVDA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. DEPO-PROVERA and FOTIVDA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	DEPO-PROVERA	FOTIVDA
Rating	64/100	New
Pharmacy pays	~$562.79 /30	—
Type	RX	RX
Active ingredient	MEDROXYPROGESTERONE ACETATE	TIVOZANIB HYDROCHLORIDE
Manufacturer	Pfizer	Aveo Pharms
Dosage forms	Injectable	Capsule
Drug class	Progestin	—
Boxed warning	Boxed warning	None
Treats	Amenorrhea, Breast Neoplasms, Renal Cell Carcinoma	Renal Cell Carcinoma

depo-provera fotivda

Rating

64/100

New

Pharmacy pays

~$562.79 /30

—

Type

Active ingredient

MEDROXYPROGESTERONE ACETATE

TIVOZANIB HYDROCHLORIDE

Manufacturer

Pfizer

Aveo Pharms

Dosage forms

Injectable

Capsule

Drug class

Progestin

—

Boxed warning

None

Treats

Amenorrhea, Breast Neoplasms, Renal Cell Carcinoma

Renal Cell Carcinoma

Frequently asked questions

What is the difference between Depo-Provera and Fotivda?

Depo-Provera contains Medroxyprogesterone Acetate, while Fotivda contains Tivozanib Hydrochloride — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.